{"id":"W4240962932","doi":"10.1093/neuonc/nox036.076","title":"OS11.5 ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temozolomide; Interim analysis; Hazard ratio; Internal medicine; Oncology; Cohort; Clinical endpoint; Confidence interval; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001118903,0.001952202,0.001457603,0.0005546195,0.0003524993,0.0009865612,0.001009922,0.001115353,0.005045536],"category_scores_gemma":[0.0006326751,0.0004595759,0.001113182,0.0003445891,0.001001834,0.0008473364,0.0003423432,0.002952912,0.001175919],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008408092,"about_ca_system_score_gemma":0.001432032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001022863,"about_ca_topic_score_gemma":0.003059617,"domain_scores_codex":[0.9997166,0.0001251819,0.00001226638,0.00004932162,0.00001943169,0.00007722462],"domain_scores_gemma":[0.9996105,0.00005379005,0.00007612063,0.00003889879,0.00002764479,0.0001930213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8886631,0.02178622,0.00116508,0.000715569,0.0007090213,0.00009024284,0.0001478199,0.001518574,0.01524587,0.0004609907,0.005108255,0.06438921],"study_design_scores_gemma":[0.8132412,0.1779001,0.00268868,0.0000545055,0.0003672643,0.000116406,0.00003895682,0.0009137609,0.002236181,0.0003253251,0.002087987,0.00002975414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865215,0.003238616,0.0009424794,0.0007529533,0.0003584283,0.002156626,0.001652999,0.0004053951,0.00397092],"genre_scores_gemma":[0.9803628,0.002842402,0.001978069,0.001479747,0.0002347671,0.003368584,0.003366472,0.00007086767,0.006296253],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005045536,"threshold_uncertainty_score":0.01687896,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0690954306968465,"score_gpt":0.4028926386686069,"score_spread":0.3337972079717604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}